Stroke · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in myocardial infarction compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in intracranial haemorrhage compared with one antiplatelet agent (low certainty).
1 finding from 1 review
Extracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual leads to higher extracranial haemorrhage compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Ischaemic stroke · preventing early recurrence after ischaemic stroke or TIA
Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Stroke · preventing early recurrence after ischaemic stroke or TIA
Multiple probably leads to lower stroke compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Multiple showed no clear difference in vascular death compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA
Multiple showed no clear difference in myocardial infarction compared with fewer antiplatelet agents (high certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA
Multiple probably leads to lower stroke, myocardial infarction, or vascular death compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Multiple may leads to higher intracranial haemorrhage compared with fewer antiplatelet agents (low certainty).
1 finding from 1 review
Extracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Multiple leads to higher extracranial haemorrhage compared with fewer antiplatelet agents (high certainty).
1 finding from 1 review
Ischaemic stroke · preventing early recurrence after ischaemic stroke or TIA
Multiple leads to lower ischaemic stroke compared with fewer antiplatelet agents (high certainty).
1 finding from 1 review
Outcomes at ≥ 3 months · preventing early recurrence after ischaemic stroke or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in any thromboembolic event compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any bleedingb compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found